Kerry Taylor

Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

Brian Druker, François Guilhot, Stephen G. O’Brien et al. · New England Journal of Medicine · 2006 · 3.5K citations · Full text

Medicine, Hematology, Oncology +13

All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)

Harry Iland, Ken Bradstock, Shane G. Supple et al. · Blood · 2012 · 340 citations · Full text

Medicine, Hematology, Oncology +15

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

Timothy P. Hughes, Susan Branford, Deborah L. White et al. · Blood · 2008 · 177 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +10

Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study

Norbert Gattermann, Carlo Finelli, Matteo Giovanni Della Porta et al. · Leukemia Research · 2010 · 177 citations

Medicine, Hematology, Internal Medicine +15

Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial

Harry Iland, Marnie Collins, Ken Bradstock et al. · The Lancet Haematology · 2015 · 170 citations

Medicine, Hematology, Oncology +10